EVRY, France, June 21, 2011 /PRNewswire/ --
Genopole® (France's leading biopark in the city of Evry, located
just south of Paris and home to 20 academic labs, 17 shared-access
technical facilities and 66 biotech companies) will be attending
(as it does every year) the BIO International Convention. The 2011
event is to take place in Washington, DC, on June 27-30.
The BIO International Convention is the largest global event for
the biotechnology industry and constitutes a great opportunity for
Genopole® to showcase its companies to potential international
partners:
- Three Genopole® portfolio companies have recently
listed on the stock market. Global Bioenergies (which
is developing a process for producing biofuels from sugars or
agricultural waste) has just raised 6.6 million on the Alternext
by NYSE Euronext market in Paris. Novagali Pharma (a
specialist in ophthalmological products) closed one of France's
largest IPOs in 2010 by raising 22 million on the NYSE Euronext
market. IntegraGen (working to identify genes involved in
autism and cancer) completed a 6.7 million stock capital increase
on Alternext. This takes the total amount of funds raised by
Genopole® portfolio companies since 1998 (when the
biopark was founded) to over 279 million.
- In 2010, Genopole® portfolio companies raised 47.8
million - a 190% year-on-year increase!
- Genopole® companies generated an estimated turnover
totaling 140 million in 2010 - a 14% increase on 2009's sales of
124 million.
At BIO 2011, Genopole® will share the Medicen Paris Region
cluster's booth (along with its partners) and is providing
organizational support to three biopark companies:
- Metabrain specializes in collaborative research on the
prevention and treatment of diabetes, obesity and Alzheimer's
disease (http://www.metabrainresearch.com).
- Texcell offers services in the fields of viral safety
and immunomonitoring. The company's US subsidiary was incorporated
in 2008 (http://www.texcell.fr).
- Nokad is developing biomarkers that predict the risk of
thrombosis(http://www.nokad-technology.com).
As France's leading biopark and with assistance from its
institutional partners (Invest in France Agency, The Economic
Development Agency, The Essonne Economic Agency, and Essonne
Chamber of Commerce and Industry), Genopole® is both underpinning
its companies' international business development activities and
seeking to attract non-French companies to locate to the campus.
This pro-active policy recently resulted in the arrival of the
French subsidiary of New England Biolabs, a global leader in the
production and the commercialization of life science research
reagents.
About Genopole®
Genopole® is the leading French science park
dedicated to life sciences. Its campus - near Paris - combines
academic (CEA, CNRS, INRA, INSERM and the University of
Evry-Val-d'Essonne) and private research laboratories,
university/higher education facilities, biotechnology companies and
an incubator for biotech start-ups.
Genopole®'s priority is to promote therapy- and
environment-focused biotech by providing optimal conditions for
company growth and progress in research, the development of
large-scale biological activities and to make France a major
competitor in the world of science and industry. Additional
information about Genopole® is available at http://www.genopole.fr
Booth 2505, French Pavilion, Hall
A
Press relations
: nicole.chemali@genopole.fr
Genopole® c ontacts : eric.lameignere@genopole.fr,
Tel.: +33-685-914-398
gabriel.mergui@genopole.fr,
Tel.: +33-680-940-455
BIOpress file:
http://www.paris-region.com
SOURCE Genopole